- Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk AnalysesZhou, J.*; Chauy, Y. -L. A.; Yooy, J. W.; Lee, S.; Ng, K.; Dee, E. C.; Liu, T.; Wai, A. K. C.; Zhang, Q.; Tse, G.CLINICAL ONCOLOGY, 2022, 34(7): E316-E317.被引 5
- Treatment-related adverse events as surrogate to response rate to immune checkpoint blockadeYanyun, Shen; Yunfeng, Chen; Duoqin, Wang; Zhidong, ZhuMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2020, 99(37): e22153.
- Psychiatric disorders associated with immune checkpoint inhibitorsZhou, C.; Lin, A.; Gu, T.; Zhang, J.; Luo, P.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
会议论文
Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) inhibitors and adverse cardiovascular events: a population-based study
2被引9阅读
